The CDC said it expects to see an increase in levels of COVID-19 and RSV in the country in the coming weeks, as they usually do during the holiday season.

The CDC expects hospitalizations for flu and COVID-19 to start increasing. It also sees increased RSV activity, particularly in young children, in the southern and eastern U.S.

The FDA approved updated COVID-19 vaccines made by Pfizer and its German partner BioNTech, as well as Moderna in August. The health regulator also granted emergency use authorization for Novavax's traditional protein-based shot.

Currently, there are three FDA-approved RSV vaccines made by GSK, Moderna and Pfizer.

As of Oct. 5, 11.2% of adults aged 18 years or above received an updated COVID-19 vaccine and 36.9% of adults 75 years or older received an RSV shot, according to CDC data.